BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.68 USD
-0.10 (-12.48%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $0.68 0.00 (0.25%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
BioLineRx Ltd. [BLRX]
Reports for Purchase
Showing records 181 - 200 ( 205 total )
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
1Q13 Highlights Movement Across the Portfolio
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Licenses An Oncologic and Decent Ciliac Disease Data
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.